EDITOR'S NOTE
A
BRAND
Lilly Lab Tour
Reveals More
Than Meets The Eye
NOVEMBER 2013
EDITORIAL DIRECTOR: Dan Schell
(814) 897-9000, Ext. 284
dan.schell@lifescienceleader.com
CHIEF EDITOR: Rob Wright
(814) 897-9000, Ext. 140
rob.wright@lifescienceconnect.com
VP OF PUBLISHING: Jon Howland
(814) 897-9000, Ext. 203
jon.howland@lifescienceleader.com
PUBLISHER, CLINICAL & CONTRACT RESEARCH:
Sean Hoffman
(724) 940-7557, Ext. 165
sean.hoffman@lifescienceleader.com
ASSOC. PUBLISHER/BIOPHARM & LAB: Shannon Primavere
(814) 897-7700, Ext. 279
shannon.primavere@lifescienceleader.com
PUBLISHER/OUTSOURCING: Cory Coleman
(814) 897-7700, Ext. 108
cory.coleman@lifescienceleader.com
GROUP PUBLISHER/OUTSOURCING: Ray Sherman
(814) 897-7700, Ext. 335
ray.sherman@lifescienceleader.com
BUSINESS DEV. MGR.: Mike Barbalaci
(814) 897-7700, Ext. 218
mike.barbalaci@lifescienceleader.com
ACCOUNT EXECUTIVE,
PACKAGING & SERIALIZATION.: Evan Lagacé
(814) 897-7700, Ext. 119
evan.lagace@lifescienceleader.com
SR. ACCOUNT EXECUTIVE: Scott Moren
(814) 897-7700, Ext. 118
scott.moren@lifescienceleader.com
PRODUCTION DIRECTOR: Lynn Netkowicz
(814) 897-9000, Ext. 205
lynn.netkowicz@jamesonpublishing.com
DIRECTOR OF AUDIENCE DEV.: Mindy Fadden
(814) 897-9000, Ext. 208
mindy.fadden@jamesonpublishing.com
Life Science Leader
5340 Fryling Rd., Suite 300
Erie, PA 16510-4672
Telephone: (814) 897-7700 ● Fax: (814) 899-4648
LIFE SCIENCE LEADER (ISSN: 21610800) Vol. 5, No. 11 is published
monthly by VertMarkets at Knowledge Park, 5340 Fryling Road,
Suite 300, Erie, PA 16510-4672. Phone (814) 897-9000, Fax (814)
899-5580. Periodical postage paid at Erie, PA 16510 and additional
mailing offices. Copyright 2013 by Peterson Partnership. All rights
reserved. Print PP. Printed in the USA.
SUBSCRIPTION RATES for qualified readers in the U.S. $0. For
non-qualified readers in the U.S. and all other countries $97 for
one year. If your mailing address is outside the U.S. or Canada,
you can receive the magazine digitally if you provide a valid email
address. POSTMASTER: Send address corrections (Form 3579) to
Life Science Leader, Knowledge Park, 5340 Fryling Road, Suite 300,
Erie, PA 16510-4672.
6
LifeScienceLeader.com
In November 2012, I wrote the cover feature story, ÒEli
Lilly and Company Ñ Open For Innovation.Ó The article
was based on an interview with Alan Palkowitz, VP of discovery chemistry, who
shared insights on Lilly's (NYSE: LLY) Open Innovation Drug Discovery (OIDD)
platform. While many companies have adopted the idea of open innovation,
actions speak louder than words. Last month, Lilly Research Laboratories (LRL)
opened its doors to a select group of media for a rare behind-the-scenes tour of
three innovation labs (Alzheimer's disease, advanced analytics, and automated
synthesis) at its global corporate headquarters in Indianapolis. My colleague
Ed Miseta, chief editor for Outsourced Pharma and Clinical Leader, and I,
along with representatives from The Wall Street Journal, Scrip Intelligence,
Indianapolis Business Journal, Indianapolis Star, and CBS and Fox TV local
affiliates, participated in a roundtable meeting with members of the LRL leadership team. During this discussion, we learned the focus of Lilly's Timely Valued
Medicines (TVM) strategy, which has resulted in the company having one of the
richest Phase 3 pipelines in its 135-year history. Of the 10 assets in Phase 3 clinical development, 9 were derived internally.
Not only did we get to hear from the leadership as to their various approaches
to R&D;, but we also got the opportunity to learn about the company's leader,
Jan Lundberg, Ph.D., who joined Lilly in 2010 as EVP of science and technology
and president of LRL.
Lundberg has authored more than 500 original articles in international peerreviewed journals and is listed as one of the most highly cited authors by the
Institute for Scientific Information (ISI). ÒIf there is nothing to conquer, then life
is boring,Ó he explained. One of the current challenges Lilly is trying to conquer
Ñ finding a cure for Alzheimer's, a lengthy process requiring perseverance. In
fact, a mantra of perseverance was evident throughout the tour.
Ronald DeMattos, Ph.D., led us through the Alzheimer's Disease Lab (in vivo),
an ailment on which he has been focused for 15+ years. Steve Ruberg, who completed his Ph.D. in biostatistics, led the group through a tour of the Advanced
Analytics Lab (in silico), demonstrating how Lilly is using computer modeling
and simulation, predictive analytics, data mining, and analysis to improve clinical study design. Alex Godfrey, Ph.D., walked the group through the only fully
integrated remote access chemistry lab in the world Ñ the Automated Synthesis
Lab (in vitro). While many have been critical of Lilly's failures, this tour revealed
that people within Lilly are learning from these experiences and view successful
drug discovery as a test of endurance to
be persevered, not merely endured. (For
additional insight into what Lilly is doing
today, check out the interview with the
company's global head of science and
Rob Wright
technology partnerships on page 30.)
rob.wright@lifescienceconnect.com
@RFWrightLSL
November 2013